ASCO: No benefit for immediate ADT after PSA-only relapse

ASCO: no benefit for immediate ADT after PSA-only relapse

(HealthDay)—For men with a prostate-specific antigen (PSA)-only-based relapse after prostate surgery or radiation therapy, there seems to be little or no survival benefit for immediate initiation of androgen deprivation therapy (ADT). These findings have been released in advance of presentation at the annual meeting of the American Society of Clinical Oncology, held from May 30 to June 3 in Chicago.

Xabier Garcia-Albeniz, M.D., from the Harvard School of Public Health in Boston, and colleagues examined the optimal timing to start ADT in patients with rising PSA as the only sign of relapse. Participants included 2,022 men in the Cancer of the Prostate Strategic Urologic Research Endeavor, staged 0.2 ng/mL [RP] or three rising determinations one month apart [RT]). Patients who initiated ADT within three months of PSA were assigned to the immediate strategy, while those who initiated ADT two or more years after PSA relapse or when they presented with metastasis, symptoms, or a short PSA doubling time were assigned to the deferred strategy. The median follow-up was 53.2 months after relapse.

The researchers found that for immediate versus deferred ADT, the hazard ratio for all-cause mortality was 1.06 (95 percent confidence interval, 0.59 to 1.89), corresponding to a −5.5 percent difference at five years. The hazard ratio for prostate-cancer specific mortality was 1.48 (95 percent confidence interval, 0.69 to 3.16), corresponding to a −5.6 percent survival difference.

"These findings suggest that there may be no need to rush to ADT," Garcia-Albeniz said in a statement.

The study was partially funded by a grant from Abbott.

More information: Press Release
More Information

Related Stories

Recommended for you

Experts set strategic priorities for lymphoma research

date 14 hours ago

A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma. The report is meant to inform future research directions as well as fund ...

Research aims to reduce health care disparities

date 14 hours ago

The lesbian, gay, bisexual, transgender/transsexual, queer/questioning and intersex (LGBTQI) population has been largely understudied by the medical community. Researchers at Moffitt Cancer Center found that the LGBTQI community ...

Promising drug target identified in medulloblastoma

date 16 hours ago

Scientists at Dana-Farber/Boston Children's Cancer and Blood Disorders Center have identified a protein critical to both the normal development of the brain and, in many cases, the development of medulloblastoma, a fast-growing ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.